FDA approved drugs:
(show all 7)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Faslodex
18
49
|
FULVESTRANT |
AstraZeneca |
April 2002 |
Disease/s that Drug Treats:Hormone receptor positive metastatic breast cancer
Indications and Usage:
18
FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer inpostmenopausal women with disease progression followingantiestrogen therapy.
DrugBank Targets:
16
1. Estrogen receptor
Mechanism of Action:
18
Target: estrogen receptors on tumor cells
Action: antagonist
FDA: Many breast cancers have estrogen receptors (ER) and thegrowth of these tumors can be stimulated by estrogen.Fulvestrant is an estrogen receptor antagonist that binds to theestrogen receptor in a competitive manner with affinitycomparable to that of estradiol and downregulates the ERprotein in human breast cancer cells.In vitro studies demonstrated that fulvestrant is a reversibleinhibitor of the growth of tamoxifen-resistant, as well asestrogen-sensitive human breast cancer (MCF-7) cell lines. Inin vivo tumor studies, fulvestrant delayed the establishment oftumors from xenografts of human breast cancer MCF-7 cellsin nude mice. Fulvestrant inhibited the growth of establishedMCF-7 xenografts and of tamoxifen-resistant breast tumorxenografts.Fulvestrant showed no agonist-type effects in in vivouterotropic assays in immature or ovariectomized mice andrats. In in vivo studies in immature rats and ovariectomizedmonkeys, fulvestrant blocked the uterotrophic action ofestradiol. In postmenopausal women, the absence of changesin plasma concentrations of FSH and LH in response tofulvestrant treatment (250 mg monthly) suggests no peripheralsteroidal effects.
|
| 2 |
|
Gleevec
18
49
|
IMATINIB MESYLATE |
Novartis |
May 2001 |
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:
18
Gleevec⢠(imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:
16
1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:
18
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
|
| 3 |
|
Keytruda
18
49
|
PEMBROLIZUMAB |
Merck |
September 2014 |
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:
18
KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:
16
1. Programmed cell death protein 1
Mechanism of Action:
18
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
|
| 4 |
|
Stivarga
18
49
|
REGORAFENIB |
Bayer/ Bayer HealthCare Pharmaceuticals |
February 2013/ September 2012 |
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:
18
Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:
16
1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:
18
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
|
| 5 |
|
Sutent
18
49
|
SUNITINIB MALATE |
Pfizer |
May 2011/ January 2006 |
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:
18
SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:
16
1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:
18
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRï¢, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFRï¢- and VEGFR2-dependent tumor angiogenesis in vivo.
|
| 6 |
|
Votrient
18
49
|
PAZOPANIB HYDROCHLORIDE |
GlaxoSmithKline |
April 2012/ October of 2009 |
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:
18
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:
16
1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:
18
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.
|
| 7 |
|
Yervoy
18
49
|
IPILIMUMAB |
Bristol-Myers Squibb |
March 2011 |
Disease/s that Drug Treats:metastatic melanoma
Indications and Usage:
18
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blockingantibody indicated for the treatment of unresectable or metastaticmelanoma. (1)
DrugBank Targets:
16
1. Cytotoxic T-lymphocyte protein 4
Mechanism of Action:
18
Target: CTLA-4
Action: blocker of interation with CD80/CD86
FDA: CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody thatbinds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockadeof CTLA-4 has been shown to augment T-cell activation and proliferation, including theactivation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signalingcan also reduce T-regulatory cell function, which may contribute to a general increase in T cellresponsiveness, including the anti-tumor immune response.
|
Drugs for Gastrointestinal Stromal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 174)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 1 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 2 |
|
Sunitinib |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
557795-19-4, 341031-54-7 |
5329102
|
|
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
5-(5-fluoro-2-oxo-1,2-Dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
|
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
| 3 |
|
Everolimus |
Approved |
Phase 4,Phase 1,Phase 2 |
|
159351-69-6 |
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 4 |
|
Sirolimus |
Approved, Investigational |
Phase 4,Phase 1,Phase 2 |
|
53123-88-9 |
46835353
6436030
5284616
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 5 |
|
Esomeprazole |
Approved, Investigational |
Phase 4 |
|
161796-78-7, 119141-88-7 |
4594
9579578
|
|
Synonyms:
( -)-Omeprazole
(-)-omeprazole
(−)-omeprazole
(-)-Omeprazole
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(s)-omeprazole
(S)-omeprazole
(S)-Omeprazole
119141-88-7
119141-89-8
131959-78-9
172964-80-6
193469-77-1
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
326602-80-6
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Alenia
Antra
Antra MUPS
AstraZeneca brand OF esomeprazole magnesium
Audazol
AULCER
Axagon
Belmazol
BIDD:GT0020
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CID9568614
CID9579578
CPD000058847
D00455
D07917
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Escz
Esofag
esomeprazol
Esomeprazol
esomeprazole
Esomeprazole
Ésoméprazole
Esomeprazole (INN)
Esomeprazole [INN:BAN]
Esomeprazole magnesium
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole Sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
esomeprazolum
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
|
LS-185188
LS-7629
Lucen
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-943-880
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium Control
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole S-form
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
SPBio_002306
STK623746
Strontium, esomeprazole
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UNII-N3PA6559FT
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
ZINC04693574
ZINC04693575
Zoltum
|
|
| 6 |
|
Caffeine |
Approved |
Phase 4 |
|
58-08-2 |
2519
|
|
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-trimethylpurine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1,3,7-Trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
137X
1gfz
1l5q
1l7x
1-methyltheobromine
1-Methyltheobromine
1-Methyl-theobromine
27602_FLUKA
2a3b
3,7-dihydro-1,3,7-Trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-dihydro-1,3,7-trimethyl-1H-purine
3,7-dihydro-1,3,7-Trimethyl-1H-purine-2,6-dione
5-26-13-00558 (Beilstein)
58-08-2
71701-02-5
75035_FLUKA
7-Methyl theophylline
7-methyltheophylline
7-Methyltheophylline
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-pep
Alert-Pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
Berlin-chemie brand OF caffeine
Berlin-Chemie Brand of Caffeine
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
bmse000206
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
Bristol-myers squibb brand OF caffeine
Bristol-Myers Squibb Brand of Caffeine
BRN 0017705
BSPBio_001921
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
Cafamil
Cafcit
Cafecon
Cafeina
Cafeína
cafeine
Cafeine
Caféine
Cafergot
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
caffeine
Caffeine (natural)
Caffeine (USP)
Caffeine [BAN:JAN]
Caffeine Pure
Caffeine solution
Caffeine, anhydrous
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, synthetic
Caffeine, Synthetic
Caffeinum
caffenium
Caffine
Cafipel
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum purrum
Coffeinum Purrum
component of Cafergot
Compound 65
CU-01000012617-3
D002110
D00528
Darvon Compound
Darvon Compound-65
Dasin
DB00201
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
DHC Plus
DHCplus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
EU-0100228
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline brand OF caffeine
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
|
Hycomine Compound
I14-4386
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
Lanorinal
Lopac0_000228
Lopac-C-0750
LS-237
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
MEGxp0_001350
Merck dura brand OF caffeine
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MLS001055341
MLS001056714
MLS001066409
MolMap_000054
MolPort-000-730-850
Monohydrate caffeine
Monomethyl derivative of Theophylline
Monomethyl Derivative of Theophylline
Natural Caffeinum
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
NCI-C02733
NCIOpen2_008255
NINDS_000730
Nix Nap
no Doz
No Doz
Nodaca
No-Doz
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
NSC 5036
NSC5036
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
Passauer brand OF caffeine
Passauer Brand of Caffeine
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Pep-Back
Percoffedrinol N
Percutafeine
Percutaféine
Phensal
Pierre fabre brand OF caffeine
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-pep
Quick-Pep
Refresh'n
Republic drug brand OF caffeine
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
Seid brand OF caffeine
Seid Brand of Caffeine
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
Spectrum_001301
SPECTRUM1500155
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Stim
STK177283
Synalgos-Dc
teina
Teina
teína
Thein
Theine
Theobromine Me
Theobromine ME
Theophylline Me
Theophylline ME
Theophylline, 7-methyl
Thompson brand 1 OF caffeine
Thompson Brand 1 of Caffeine
Thompson brand 2 OF caffeine
Thompson Brand 2 of Caffeine
Tirend
TNP00310
Triad
Tri-Aqua
Ultra Pep-Back
UNII-3G6A5W338E
Vivarin
W222402_ALDRICH
Wake-Up
Wigraine
WLN: T56 BN DN FNVNVJ B1 F1 H1
Xanthine, 1,3,7-trimethyl
ZINC00001084
|
|
| 7 |
|
Midazolam |
Approved, Illicit |
Phase 4,Phase 1 |
|
59467-70-8 |
4192
|
|
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
Dazolam
DB00683
Dea no. 2884
Dea No. 2884
DEA No. 2884
Dormicum
Dormicum (TN)
EINECS 261-774-5
|
Hydrochloride, midazolam
LS-77780
Maleate, midazolam
Midanium
midazolam
Midazolam
Midazolam (JAN/INN)
Midazolam [INN:BAN:JAN]
Midazolam base
Midazolam Base
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
nchembio747-comp32
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
|
|
| 8 |
|
Angiogenesis Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 9 |
|
Angiogenesis Modulating Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 10 |
|
Cola |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 11 |
|
Liver Extracts |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 12 |
|
Imatinib Mesylate |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
220127-57-1 |
123596
|
| 13 |
|
Protein Kinase Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 14 |
|
Anesthetics |
|
Phase 4,Phase 3,Phase 1,Not Applicable |
|
|
|
| 15 |
|
Immunologic Factors |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 16 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 1,Phase 2 |
|
|
|
| 17 |
|
Antacids |
|
Phase 4 |
|
|
|
| 18 |
|
Gastrointestinal Agents |
|
Phase 4,Phase 2 |
|
|
|
| 19 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
| 20 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
| 21 |
|
Anesthetics, General |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 22 |
|
Adjuvants, Anesthesia |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 23 |
|
GABA Modulators |
|
Phase 4,Phase 1 |
|
|
|
| 24 |
|
Hypnotics and Sedatives |
|
Phase 4,Phase 1 |
|
|
|
| 25 |
|
Anesthetics, Intravenous |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 26 |
|
Pharmaceutical Solutions |
|
Phase 4,Phase 3 |
|
|
|
| 27 |
|
GABA Agents |
|
Phase 4,Phase 1 |
|
|
|
| 28 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
| 29 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 1 |
|
|
|
| 30 |
|
Tranquilizing Agents |
|
Phase 4,Phase 1 |
|
|
|
| 31 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
| 32 |
|
Anti-Anxiety Agents |
|
Phase 4,Phase 1 |
|
|
|
| 33 |
|
Purinergic P1 Receptor Antagonists |
|
Phase 4 |
|
|
|
| 34 |
|
Erlotinib Hydrochloride |
|
Phase 4,Phase 1 |
|
183319-69-9 |
176871
|
|
Synonyms:
|
| 35 |
|
Psychotropic Drugs |
|
Phase 4,Phase 1 |
|
|
|
| 36 |
|
Central Nervous System Depressants |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 37 |
|
Formaldehyde |
Approved, Vet_approved |
Phase 3 |
|
50-00-0 |
712
|
|
Synonyms:
Aldeide formica
Fannoform
Formaldehyd
Formaldehyde solution
Formalin
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
Formol
|
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde
|
|
| 38 |
|
Bevacizumab |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
| 39 |
|
Dasatinib |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Not Applicable |
|
302962-49-8 |
3062316
|
|
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(18F)-N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
anh. dasatinib
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS Dasatinib
BMS354825
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
|
dasatinibum
Dasatinibum
DB01254
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-METHYLPHENYL)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
NSC732517
NSC-732517
S1021_Selleck
Sprycel
SPRYCEL (TN)
Spyrcel
UNII-X78UG0A0RN
|
|
| 40 |
|
Orange |
Approved |
Phase 2, Phase 3 |
|
|
|
| 41 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 42 |
|
Lactitol |
Investigational |
Phase 2, Phase 3 |
|
585-86-4 |
3871
|
|
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
lactitol
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
| 43 |
|
Crenolanib |
Investigational |
Phase 3,Phase 2 |
|
670220-88-9 |
10366136
|
|
Synonyms:
|
| 44 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3,Phase 1 |
|
59763-91-6 |
|
| 45 |
|
tyrosine |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 46 |
|
Immunoglobulins |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 47 |
|
Antibodies |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 48 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
| 49 |
|
Antibodies, Monoclonal |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 50 |
|
Endothelial Growth Factors |
|
Phase 3,Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 286)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors |
Unknown status |
NCT00777504
|
Phase 4 |
usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor |
| 2 |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer |
Unknown status |
NCT00274885
|
Phase 4 |
oxaliplatin |
| 3 |
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib |
Active, not recruiting |
NCT00756509
|
Phase 4 |
Nilotinib |
| 4 |
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor |
Completed |
NCT00793871
|
Phase 4 |
Sunitinib Malate (SU011248) |
| 5 |
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) |
Completed |
NCT00171977
|
Phase 4 |
Imatinib Mesylate |
| 6 |
Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate |
Completed |
NCT00510354
|
Phase 4 |
Imatinib mesylate |
| 7 |
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib |
Completed |
NCT02800330
|
Phase 4 |
Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg |
| 8 |
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients |
Completed |
NCT01402089
|
Phase 4 |
Sunitinib;Erlotinib;Midazolam;Caffeine |
| 9 |
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor |
Unknown status |
NCT00685828
|
Phase 3 |
imatinib mesylate |
| 10 |
EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs |
Unknown status |
NCT02866045
|
Phase 3 |
|
| 11 |
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate |
Terminated |
NCT00956072
|
Phase 3 |
imatinib mesylate |
| 12 |
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index |
Not yet recruiting |
NCT02576080
|
Phase 3 |
Imatinib |
| 13 |
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor |
Completed |
NCT00103168
|
Phase 3 |
imatinib mesylate |
| 14 |
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib |
Recruiting |
NCT01694277
|
Phase 3 |
Masitinib;Sunitinib |
| 15 |
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) |
Terminated |
NCT00812240
|
Phase 3 |
Masitinib;Imatinib |
| 16 |
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. |
Completed |
NCT01289028
|
Phase 3 |
Nilotinib |
| 17 |
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) |
Active, not recruiting |
NCT01271712
|
Phase 3 |
Regorafenib (Stivarga, BAY73-4506);Placebo;Best supportive care |
| 18 |
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor |
Terminated |
NCT00324987
|
Phase 3 |
Imatinib Mesylate |
| 19 |
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors |
Completed |
NCT00293124
|
Phase 3 |
Glivec |
| 20 |
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors |
Terminated |
NCT00372567
|
Phase 3 |
sunitinib malate;imatinib mesylate |
| 21 |
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor |
Terminated |
NCT00009906
|
Phase 3 |
Imatinib Mesylate |
| 22 |
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery |
Completed |
NCT00041197
|
Phase 3 |
imatinib mesylate |
| 23 |
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) |
Completed |
NCT00075218
|
Phase 3 |
Placebo;SU011248 |
| 24 |
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions |
Completed |
NCT02103322
|
Phase 2, Phase 3 |
Imatinib Mesylate Tablets, 400 mg;Imatinib Mesylate Tablets, 400 mg |
| 25 |
L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors |
Recruiting |
NCT03426722
|
Phase 3 |
L-carnitine;Placebo |
| 26 |
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) |
Completed |
NCT01462994
|
Phase 3 |
|
| 27 |
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg |
Terminated |
NCT00751036
|
Phase 3 |
Nilotinib;Imatinib |
| 28 |
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence |
Terminated |
NCT02009423
|
Phase 3 |
Masitinib;Placebo |
| 29 |
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib |
Completed |
NCT00471328
|
Phase 3 |
Nilotinib |
| 30 |
Rechallenge of Imatinib in GIST Having no Effective Treatment |
Completed |
NCT01151852
|
Phase 3 |
Imatinib;Placebo |
| 31 |
A Study of Nilotinib Versus Imatinib in GIST Patients |
Completed |
NCT00785785
|
Phase 3 |
Nilotinib (AMN107);imatinib (STI571) |
| 32 |
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
Recruiting |
NCT02260505
|
Phase 3 |
Imatinib maintenance |
| 33 |
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients |
Terminated |
NCT01031628
|
Phase 3 |
Imatinib mesylate;Imatinib mesylate;Imatinib mesylate |
| 34 |
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib |
Recruiting |
NCT03673501
|
Phase 3 |
DCC-2618;Sunitinib |
| 35 |
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies |
Active, not recruiting |
NCT03353753
|
Phase 3 |
DCC-2618;Placebo Oral Tablet |
| 36 |
Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance |
Completed |
NCT00367861
|
Phase 3 |
interruption of Glivec® |
| 37 |
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib |
Terminated |
NCT00688766
|
Phase 3 |
retaspimycin hydrochloride (IPI-504);placebo |
| 38 |
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) |
Completed |
NCT00116935
|
Phase 3 |
imatinib mesylate;imatinib;imatinib |
| 39 |
Caphosol in Oral Mucositis Due to Targeted Therapy |
Completed |
NCT01265810
|
Phase 3 |
|
| 40 |
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST |
Recruiting |
NCT03465722
|
Phase 3 |
avapritinib;regorafenib |
| 41 |
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST |
Recruiting |
NCT02847429
|
Phase 3 |
Crenolanib;Placebo |
| 42 |
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST |
Recruiting |
NCT02413736
|
Phase 3 |
Imatinib |
| 43 |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
Completed |
NCT00538850
|
Phase 3 |
Fentanyl sublingual spray;Placebo |
| 44 |
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis |
Completed |
NCT00033943
|
Phase 2, Phase 3 |
deligoparin |
| 45 |
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) |
Unknown status |
NCT00290485
|
Phase 2 |
Imatinib mesylate |
| 46 |
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation |
Unknown status |
NCT02606097
|
Phase 2 |
regorafenib |
| 47 |
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT |
Unknown status |
NCT02931929
|
Phase 1, Phase 2 |
68Ga-NeoBOMB1, 2-vial kit |
| 48 |
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma |
Unknown status |
NCT00780494
|
Phase 2 |
bevacizumab;carboplatin;capecitabine |
| 49 |
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer |
Unknown status |
NCT01019798
|
Phase 2 |
sunitinib, docetaxel, cisplatin |
| 50 |
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors |
Unknown status |
NCT01803503
|
Phase 2 |
Docetaxel;Sunitinib |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
|
